(BUFFALO, NY) September 3, 2019 – Efferent Labs, Inc., a developer of high-value medical technology and devices, is pleased to announce its relocation to a state-of-the-art facility in Buffalo, NY on September 1, 2019.
“We are very excited to announce our move to the Hauptman-Woodward Medical Research Institute, located across the street from our location of the last 4 years: UB CBLS facility. This move will provide much needed lab space for our continued efforts toward the commercialization of the CytoComm™ biosensor system”, said Bill Rader, CEO Efferent Labs.
As a start-up biotech company Efferent Labs has historically contracted laboratory facilities in Rochester, NY and at partner sites in Europe. With the addition of in-house labs, the company will increase its research footprint allowing more development and testing of the companies biosensor system and software.
More information about Efferent Labs and CytoComm™ can be found at www.efferentlabs.com.
About Efferent Labs
Efferent Labs is a developer of high value medical diagnostic technology. Efferent Labs’ proprietary technology is CytoComm™ Living Cell Biosensor platform that is used for in-vivo, real time monitoring of physiological variables that leverage the ability to use biological signaling and cellular response. Efferent Labs is based in Buffalo, NY and is a 2014 43North award winner. FOR MORE INFORMATION CONTACT: firstname.lastname@example.org